Characterization and Modulation of the Immunosuppressive Phase of Sepsis
Open Access
- 1 April 2010
- journal article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 78 (4) , 1582-1592
- https://doi.org/10.1128/iai.01213-09
Abstract
Sepsis continues to cause significant morbidity and mortality in critically ill patients. Studies of patients and animal models have revealed that changes in the immune response during sepsis play a decisive role in the outcome. Using a clinically relevant two-hit model of sepsis, i.e., cecal ligation and puncture (CLP) followed by the induction of Pseudomonas aeruginosa pneumonia, we characterized the host immune response. Second, AS101 [ammonium trichloro(dioxoethylene-o,o')tellurate], a compound that blocks interleukin 10 (IL-10), a key mediator of immunosuppression in sepsis, was tested for its ability to reverse immunoparalysis and improve survival. Mice subjected to pneumonia following CLP had different survival rates depending upon the timing of the secondary injury. Animals challenged with P. aeruginosa at 4 days post-CLP had approximately 40% survival, whereas animals challenged at 7 days had 85% survival. This improvement in survival was associated with decreased lymphocyte apoptosis, restoration of innate cell populations, increased proinflammatory cytokines, and restoration of gamma interferon (IFN-gamma) production by stimulated splenocytes. These animals also showed significantly less P. aeruginosa growth from blood and bronchoalveolar lavage fluid. Importantly, AS101 improved survival after secondary injury 4 days following CLP. This increased survival was associated with many of the same findings observed in the 7-day group, i.e., restoration of IFN-gamma production, increased proinflammatory cytokines, and decreased bacterial growth. Collectively, these studies demonstrate that immunosuppression following initial septic insult increases susceptibility to secondary infection. However, by 7 days post-CLP, the host's immune system has recovered sufficiently to mount an effective immune response. Modulation of the immunosuppressive phase of sepsis may aid in the development of new therapeutic strategies.Keywords
This publication has 36 references indexed in Scilit:
- Stratification is the key: Inflammatory biomarkers accurately direct immunomodulatory therapy in experimental sepsis*Critical Care Medicine, 2009
- Sepsis-induced human lymphocyte apoptosis and cytokine production in “humanized” miceJournal of Leukocyte Biology, 2009
- Harmful molecular mechanisms in sepsisNature Reviews Immunology, 2008
- Pathophysiology of SepsisThe American Journal of Pathology, 2007
- BACTERIAL CLEARANCE AND MORTALITY ARE NOT IMPROVED BY A COMBINATION OF IL-10 NEUTRALIZATION AND IFN-γ ADMINISTRATION IN A MURINE MODEL OF POST-CLP IMMUNOSUPPRESSIONShock, 2006
- Bacterial Clearance and Cytokine Profiles in a Murine Model of Postsurgical Nosocomial PneumoniaClinical and Vaccine Immunology, 2004
- DIMINISHED BACTERIAL CLEARANCE IS ASSOCIATED WITH DECREASED IL-12 AND INTERFERON-?? PRODUCTION BUT A SUSTAINED PROINFLAMMATORY RESPONSE IN A MURINE MODEL OF POSTSEPTIC IMMUNOSUPPRESSIONShock, 2004
- Nosocomial Infections Adversely Affect the Outcomes of Patients with Serious Intraabdominal InfectionsSurgical Infections, 2004
- The Pathophysiology and Treatment of SepsisNew England Journal of Medicine, 2003
- Early Interleukin-10 Treatment Improves Survival and Enhances Immune Function Only in Males After Hemorrhage and Subsequent SepsisShock, 2002